Literature DB >> 26629272

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629272      PMCID： PMC4665064     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

1.  Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota.

Authors:  Kurtis B Reed; Jerry D Brewer; Christine M Lohse; Kariline E Bringe; Crystal N Pruitt; Lawrence E Gibson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  Incidence of childhood and adolescent melanoma in the United States: 1973-2009.

Authors:  Jeannette R Wong; Jenine K Harris; Carlos Rodriguez-Galindo; Kimberly J Johnson
Journal:  Pediatrics       Date:  2013-04-15       Impact factor: 7.124

Review 3.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

4.  Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.

Authors:  Keith L Davis; Debanjali Mitra; Srividya Kotapati; Ramy Ibrahim; Jedd D Wolchok
Journal:  Appl Health Econ Health Policy       Date:  2009       Impact factor: 2.561
  4 in total
  30 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 2.  Thyroid dysfunctions secondary to cancer immunotherapy.

Authors:  P Chalan; G Di Dalmazi; F Pani; A De Remigis; A Corsello; P Caturegli
Journal:  J Endocrinol Invest       Date:  2017-12-13       Impact factor: 4.256

3.  Pembrolizumab-Induced Microscopic Colitis.

Authors:  Monjur Ahmed; Gloria Francis
Journal:  Am J Gastroenterol       Date:  2018-04       Impact factor: 10.864

Review 4.  Advances in systemic therapy for metastatic breast cancer: future perspectives.

Authors:  S P Corona; N Sobhani; A Ianza; G Roviello; G Mustacchi; M Bortul; F Zanconati; D Generali
Journal:  Med Oncol       Date:  2017-05-19       Impact factor: 3.064

Review 5.  Immune checkpoint pathways in non-small cell lung cancer.

Authors:  Young Kwang Chae; Ayush Arya; Wade Iams; Marcello Cruz; Nisha Mohindra; Victoria Villaflor; Francis J Giles
Journal:  Ann Transl Med       Date:  2018-03

6.  High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases.

Authors:  Satyendra Singh; Ketan Kumar; Mamta Panda; Aryan Srivastava; Amit Mishra; Vijay Kumar Prajapati
Journal:  Mol Divers       Date:  2022-05-28       Impact factor: 2.943

Review 7.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

8.  Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.

Authors:  Fauzia Riaz; Geliang Gan; Fangyong Li; Amy J Davidoff; Kerin B Adelson; Carolyn J Presley; Blythe J Adamson; Pooja Shaw; Ravi B Parikh; Ronac Mamtani; Cary P Gross
Journal:  JCO Oncol Pract       Date:  2020-07-17

Review 9.  Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review.

Authors:  Xinsheng Li; Ya Liang; Jingfan Wang; Zizhong Hu; Zhi-Lan Yuan; Ping Xie
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.